VRXA
Veraxa Biotech Holding AG • NASDAQ
$2.12 ▲ 1.44% (+0.03)
VRXA
Veraxa Biotech Holding AGNASDAQ • $2.12 ▲ 1.44% (+0.03)
Market Cap $296.96 M
52w High $27.36
52w Low $1.70
P/E -3.66
Volume 161.59K
Outstanding Shares 141.41M
Market Cap $296.96 M
52w High $27.36
52w Low $1.70
P/E -3.66
Volume 161.59K
Outstanding Shares 141.41M
About Veraxa Biotech Holding AG
https://www.veraxa.comVeraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65].
CEO
Christoph Antz
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public June 9, 2026
Method of going public SPAC
Full time employees 8
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0